A prospective trial of adjuvant therapy for high-risk melanoma

Patients diagnosed with iris, ciliary body or choroidal melanoma of high-risk tumour cytogenetics (monosomy 3>/= 20% of cells), were treated with adjuvant low-dose dacarbacine (DTIC) and interferon –alpha-2b (IFNA-2b), following primary treatment (enucleation, brachytherapy or resection). DTIC was given intravenously...

A mouse model for uveal melanoma

Uveal melanoma (UM) is the most common malignant tumour arising within the eye and is a severe threat for both sight and life, due to a high risk of metastasis. There are no animal models of UM, but the Tg(Grm1)...